Dose differences between patients treated with MR-only, CT-only, or MR-CT fusion radiotherapy for prostate cancer
The dose benefit from MR-only has been assessed in clinical practice, demonstrating significant reductions in penile bulb and rectum doses compared to both CT-only and MR-CT pathways. This suggests the MR-only pathway is required to provide the full benefit of MR contouring to reduce toxicities from prostate radiotherapy.
Authors
- Serena West
- Stephen Hedley
- T. Wintle
- Neil D. Richmond (ORCID: https://orcid.org/0000-0003-0835-296X)
- R. Pearson (ORCID: https://orcid.org/0000-0002-7822-5037)
- J. Wyatt (ORCID: https://orcid.org/0000-0003-0748-0791)
- R. Pearson (ORCID: https://orcid.org/0000-0003-4893-493X)
Institutions
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
Publication Details
- Journal
- British Journal of Radiology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1093/bjr/tqaf159
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52